Weight-Loss Drugs Wegovy & Foundayo Get Medicare Coverage on July 1, 2026 – Find Out Who Qualifies – Image for illustrative purposes only (Image credits: Unsplash)
Millions of older Americans have long faced high out-of-pocket costs for medications that treat obesity and related conditions. A new temporary initiative from Medicare aims to change that starting next month. The Medicare GLP-1 Bridge program will make certain weight-loss drugs available at a much lower monthly cost for those who meet specific requirements.
Medicare Expands Access to GLP-1 Medications
Federal rules have historically barred Medicare from covering drugs prescribed primarily for weight loss. The new bridge program creates a separate pathway that allows approved GLP-1 medications to reach beneficiaries who need them for documented health reasons. Wegovy and Foundayo are included from the start, along with select versions of Zepbound.
The change reflects growing recognition that these medications can help manage cardiovascular risks, blood sugar levels, and other complications tied to excess weight. Officials expect the program to run as a demonstration through the end of 2027, giving time to evaluate its effects before any longer-term decisions.
Who Qualifies Under the New Rules
Eligibility begins with enrollment in a Medicare Part D plan or a Medicare Advantage plan that includes prescription coverage. Clinical criteria are also required. Beneficiaries generally need a body mass index of 35 or higher, or a BMI of at least 27 when accompanied by conditions such as heart disease, high blood pressure, prediabetes, or sleep apnea.
Physicians must submit prior authorization requests that document medical necessity. Not every Medicare enrollee will meet these standards, even if they are the right age. Those whose records do not show qualifying health issues may still face denial despite meeting the age requirement.
Expected Cost Reductions and Health Considerations
Many retirees have paid between $900 and $1,300 each month for these medications without coverage. The bridge program sets a flat copay near $50 for approved users, a shift that could ease financial pressure for people on fixed incomes. Lower costs may encourage consistent use under medical supervision.
Doctors note that sustained weight management can improve mobility, reduce joint strain, and lower the chance of future complications. The program does not guarantee results for every patient, and individual responses vary based on overall health and adherence to treatment plans.
Key Limits and Steps to Prepare
The coverage remains temporary and excludes some medication formulations. Certain Zepbound versions, for example, fall outside the current scope. Ongoing monitoring and paperwork requirements will continue even after approval.
Seniors who believe they may qualify should review their current drug plan details now. Scheduling a visit with a healthcare provider to discuss BMI records and related conditions can help avoid delays once the July 1 start date arrives. Checking for any updates from the Centers for Medicare and Medicaid Services will also keep expectations aligned with final guidance.
